Biomarker PAX5 for sepsis-related diseases and use thereof
By detecting PAX5 levels in peripheral blood immune cells, a biomarker for the early diagnosis and prognosis of sepsis is provided, solving the problem of difficulty in early diagnosis of sepsis in existing technologies and improving the accuracy of diagnosis and the timeliness of treatment.
Patent Information
- Application Number
- PCT/CN2025/109250
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-07-19
- Filing Date
- 2025-07-18
- Publication Date
- 2026-01-22
AI Technical Summary
Current technologies lack specific molecular markers for early diagnosis of sepsis before organ dysfunction occurs, leading to delayed treatment and impacting patient survival rates.
By utilizing PAX5 as a biomarker, and detecting PAX5 levels in peripheral blood immune cells, we aim to develop products and methods for the early diagnosis, risk assessment, immune status evaluation, prognosis prediction, and treatment selection of sepsis.
It enables early diagnosis of sepsis when the SOFA score is below 2, improving diagnostic sensitivity and specificity, reducing the risk of patient death due to treatment delay, and demonstrating good diagnostic efficacy. ROC analysis showed that the AUC was 0.8, which exceeded the diagnostic efficacy of the commonly used clinical indicator PCT.